Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-26T15:56:05.908Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic science (October 2005)

Published online by Cambridge University Press:  22 March 2006

R. Sutherland  and
J. Scorer
R. Sutherland
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
J. Scorer
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Journals Watch
Information
Breast Cancer Online , Volume 9 , Issue 4 , April 2006 , pp. 1 - 3 , e17
Copyright
2006 Cambridge University Press

References

Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE. Curcumin suppresses the paclitaxel-induced nuclear factor-kappa B pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005; 11: 7490–7498.Google Scholar
Bowen TJ, Yakushiji H, Montagna C, Jain S, Ried T, Wynshaw-Boris A. Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching. Cancer Res 2005; 65: 8736–8746.Google Scholar
Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005; 6: 798–808.Google Scholar
Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005; 23: 7350–7360.Google Scholar
Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Boillot C, Rinaldi S, Llewellyn M, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PHM, Pera G, Barricarte A, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: Results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomar Prevent 2005; 14: 2316–2325.Google Scholar
Chen JQ, Yager JD, Russo J. Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/pathophysiological implications. BiochimEt Biophys Acta Mol Cell Res 2005; 1746: 1–17.Google Scholar
Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between Polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomar Prevent 2005; 14: 2335–2339.Google Scholar
Chen ZT, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE, Singh RK. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 2005; 65: 9004–9011.Google Scholar
Cheng CK, Chow LWC, Loo WTY, Chan TK, Chan V. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 2005; 65: 8646–8654.Google Scholar
Cui XJ, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23: 7721–7735.Google Scholar
Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska E, Haus O, Grzybowska E, Stawicka M, Swiec M, Urbanski K, Niepsuj S, Wasko B, Gozdz S, Wandzel P, Szczylik C, Surdyka D, Rozmiarek A, Zambrano O, Posmyk M, Narod SA, Lubinski J. A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 2005; 42: 763–765.Google Scholar
Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005; 23: 7512–7517.Google Scholar
Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA. Breast cancer risk following bilateral oophorectorny in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol 2005; 23: 7491–7496.Google Scholar
Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005; 165: 2264–2271.Google Scholar
Espinosa E, Vara JAF, Redondo A, Sanchez JJ, Hardisson D, Zamora P, Pastrana FG, Cejas P, Martinez B, Suarez A, Calero F, Baron MG. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 2005; 23: 7278–7285.Google Scholar
Farabegoli F, Ceccarelli C, Santini D, Taffurelli M. Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol 2005; 58: 1046–1050.Google Scholar
Folgueira M, Carraro DM, Brentani H, Patra DFD, Barbosa EM, Netto MM, Caldeira JRF, Katayama MLH, Soares FA, Oliveira CT, Reis LFL, Kaiano JHL, Camargo LP, Vencio RZN, Snitcovsky IML, Makdissi FBA, Silva P, Goes J, Brentani MM. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005; 11: 7434–7443.Google Scholar
Garvin S, Nilsson UW, Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer 2005; 93: 1005–1010.Google Scholar
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265–7277.Google Scholar
Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 2005; 23: 7098–7104.Google Scholar
Grimm SL, Contreras A, Barcellos-Hoff MH, Rosen JM. Cell cycle defects contribute to a block in hormone-induced mammary gland proliferation in CCAAT/enhancer-binding protein (C/EBP beta)-null mice. J Biol Chem 2005; 280: 36301–36309.Google Scholar
Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA. Estrogen receptors alfa (ER alpha) and beta (ER beta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005; 24: 6605–6616.Google Scholar
Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkila N, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benitez J. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol 2005; 23: 7503–7511.Google Scholar
Hopper JL, Hayes VM, Spurdle AB, Chenevix-Trench G, Jenkins MA, Milne RL, Dite GS, Tesoriero AA, McCredie MRE, Giles GG, Southey MC. A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancer. Hum Mutat 2005; 26: 298–302.Google Scholar
Hui L, Rodrik V, Pielak RM, Knirr S, Zheng Y, Foster DA. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J Biol Chem 2005; 280: 35829–35835.Google Scholar
Johnson N, Fletcher O, Naceur-Lombardelli C, Silva ID, Ashworth A, Peto J. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005; 366: 1554–1557.Google Scholar
Khalili P, Arakelian A, Chen GP, Singh G, Rabbani SA. Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene 2005; 24: 6657–6666.Google Scholar
Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JMS. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005; 207: 139–146.Google Scholar
Kronblad A, Hedenfalk I, Nilsson E, Pahlmann S, Landberg G. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ER alpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 2005; 24: 6835–6841.Google Scholar
Laakso M, Loman N, Borg A, Isola J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005; 18: 1321–1328.Google Scholar
Lund CV, Popkov M, Magnenat L, Barbas CF. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. Mol Cell Biol 2005; 25: 9082–9091.Google Scholar
Magnusson CMK, Roddam AW, Pike MC, Chilvers C, Crossley B, Hermon C, McPherson K, Peto J, Vessey M, Beral V. Body fatness and physical activity at young ages and the risk of breast cancer in premenopausal women. Br J Cancer 2005; 93: 817–824.Google Scholar
Martin NL, Saba-El-Leil MK, Sadekova S, Meloche S, Sauvageau G. EN2 is a candidate oncogene in human breast cancer. Oncogene 2005; 24: 6890–6901.Google Scholar
Martin RM, Middleton N, Gunnell D, Owen CG, Smith GD. Breast-feeding and cancer: The Boyd Orr cohort and a systematic review with meta-analysis. J Natl Cancer Inst 2005; 97: 1446–1457.Google Scholar
Maskarinec G, Pagano I, Lurie G, Wilkens LR, Kolonel LN. Mammographic density and breast cancer risk – The multiethnic cohort study. Am J Epidemiol 2005; 162: 743–752.Google Scholar
Millikan RC, Player JS, deCotret AR, Tse CK, Keku T. Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk. Cancer Epidemiol Biomar Prevent 2005; 14: 2326–2334.Google Scholar
Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI. Genetic testing in an ethnically diverse cohort of high-risk women – a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005; 294: 1925–1933.Google Scholar
Noruzinia M, Coupier I, Pujol P. Is BRCA1/ BRCA2-related breast carcinogenesis estrogen dependent? Cancer 2005; 104: 1567–1574.Google Scholar
Poola I, Fuqua SAW, De Witty RL, Abraham J, Marshallack J, Liu AY. Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ER beta 1 and ER beta 5: Potential molecular targets for chernoprevention. Clin Cancer Res 2005; 11: 7579–7585.Google Scholar
Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: Potential implications for tumor progression. Cancer Res 2005; 65: 8896–8904.Google Scholar
Rakha EA, Boyce RWG, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JFR, Ellis IO. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18: 1295–1304.Google Scholar
Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman A, Garcia RR, Arnold M, Goedheer AJW, Portengen H, Klijn JGM, Foekens JA. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 2005; 11: 7311–7321.Google Scholar
Tynan JA, Wen F, Muller WJ, Oshima RG. Ets2-dependent microenvironmental support of mouse mammary tumors. Oncogene 2005; 24: 6870–6876.Google Scholar
Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212–7220.Google Scholar
Wang XJ, Li N, Li HZ, Liu B, Qiu JM, Chen TY, Cao XT. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest. Clin Cancer Res 2005; 11: 7545–7553.Google Scholar
Weigelt B, Hu ZY, He XP, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, van't Veer LJ. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005; 65: 9155–9158.Google Scholar
Weigelt B, Wessels LFA, Bosma AJ, Glas AM, Nuyten DSA, He YD, Dai H, Peterse JL, van't Veer LJ. No common denominator for breast cancer lymph node metastasis. Br J Cancer 2005; 93: 924–932.Google Scholar
Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167: 913–920.Google Scholar
Xu Y, Yao LH, Ouyang T, Li JF, Wang TF, Fan ZQ, Lin BY, Lu YY, Xie YT. p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005; 11: 7328–7333.Google Scholar